These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20678312)

  • 1. Clostridium difficile bacteremia, Taiwan.
    Lee NY; Huang YT; Hsueh PR; Ko WC
    Emerg Infect Dis; 2010 Aug; 16(8):1204-10. PubMed ID: 20678312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
    Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone resistance and Clostridium difficile, Germany.
    Zaiss NH; Witte W; Nübel U
    Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
    Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
    Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002].
    Pituch H; Obuch-Woszczatyński P; Glinka D; Łazińska B; Meisel-Mikołajczyk F; Łuczak M
    Med Dosw Mikrobiol; 2003; 55(3):253-8. PubMed ID: 14702667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
    Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of Clostridium difficile bacteremia in a patient with loop ileostomy.
    Choi JL; Kim BR; Kim JE; Woo KS; Kim KH; Kim JM; Lee SE; Han JY
    Ann Lab Med; 2013 May; 33(3):200-2. PubMed ID: 23667848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population.
    Mezoff E; Mann EA; Hart KW; Lindsell CJ; Cohen MB
    J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):437-41. PubMed ID: 21407116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of linezolid against Clostridium difficile.
    Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
    Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
    Johnson S; Gerding DN; Louie TJ; Ruiz NM; Gorbach SL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4043-5. PubMed ID: 22615287
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.
    Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB
    Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activities of nitazoxanide against Clostridium difficile.
    McVay CS; Rolfe RD
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2254-8. PubMed ID: 10952564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea.
    Clutter DS; Dubrovskaya Y; Merl MY; Teperman L; Press R; Safdar A
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4501-5. PubMed ID: 23836168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two case reports of Clostridium difficile bacteremia, one with the epidemic NAP-1 strain.
    Hemminger J; Balada-Llasat JM; Raczkowski M; Buckosh M; Pancholi P
    Infection; 2011 Aug; 39(4):371-3. PubMed ID: 21509425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
    Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
    Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.
    Butler MM; Shinabarger DL; Citron DM; Kelly CP; Dvoskin S; Wright GE; Feng H; Tzipori S; Bowlin TL
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4786-92. PubMed ID: 22733075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.